East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cimetidine Tablets USP, 200 mg, 300 mg, 400 mg, and 800 mg. Aurobindo Pharma’s Cimetidine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Tagamet® Tablets manufactured by Glaxosmithkline (GSK).

Cimetidine Tablets are indicated for:

• Short-term treatment of active duodenal ulcer
• Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer
• Short-term treatment of active benign gastric ulcer
• Erosive gastroesophageal reflux (GERD)
• The treatment of pathological hypersecretory conditions.